Clinical Significance of SASH1 Expression in Glioma

Abstract EN

Objective.

SAM and SH3 domain containing 1 (SASH1) is a recently discovered tumor suppressor gene.

The role of SASH1 in glioma has not yet been described.

We investigated SASH1 expression in glioma cases to determine its clinical significance on glioma pathogenesis and prognosis.

Methods.

We produced tissue microarrays using 121 patient-derived glioma samples and 30 patient-derived nontumor cerebral samples.

Immunohistochemistry and Western blotting were used to evaluate SASH1 expression.

We used Fisher’s exact tests to determine relationships between SASH1 expression and clinicopathological characteristics; Cox regression analysis to evaluate the independency of different SASH1 expression; Kaplan-Meier analysis to determine any correlation of SASH1 expression with survival rate.

Results.

SASH1 expression was closely correlated with the WHO glioma grade.

Of the 121 cases, 66.9% with low SASH1 expression were mostly grade III-IV cases, whereas 33.1% with high SASH1 expression were mostly grades I-II.

Kaplan-Meier analysis revealed a significant positive correlation between SASH1 expression and postoperative survival.

Conclusions.

SASH1 was widely expressed in normal and low-grade glioma tissues.

SASH1 expression strongly correlated with glioma grades, showing higher expression at a lower grade, which decreased significantly as grade increased.

Furthermore, SASH1 expression was positively correlated with better postoperative survival in patients with glioma.